New ntm treatment guidelines recommend insmed's arikayce® (amikacin liposome inhalation suspension) for treatment of patients with refractory mac lung disease

Bridgewater, n.j., july 7, 2020 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that arikayce® (amikacin liposome inhalation suspension) has been included...
INSM Ratings Summary
INSM Quant Ranking